Post-Streptococcal Autoimmunity and EBV as Contributors to Multiple Sclerosis

Overview

Epstein–Barr virus (EBV) infection is implicated as a necessary factor in the development of multiple sclerosis (MS), with molecular mimicry and latent viral reactivation proposed as mechanisms. Analogous to group A streptococcus (GAS) triggering acute rheumatic fever (ARF), EBV-driven immune responses may drive MS disease activity, suggesting antiviral treatment of infectious mononucleosis (IM) could prevent MS onset and progression.

Background

Multiple sclerosis is a chronic autoimmune neurological disorder with unclear etiology, though EBV infection is strongly linked to its development. While EBV exposure is widespread, only a subset of individuals develop MS, indicating additional factors contribute to disease manifestation. GAS infection is a well-established trigger of autoimmune sequelae such as ARF, providing a model for understanding infection-driven autoimmunity. EBV differs by establishing latent infection with intermittent reactivation, potentially driving MS disease activity through immune mechanisms.

Data Highlights

People with a history of infectious mononucleosis have more than double the risk of developing MS compared to those without such history. Approximately 30% of university students experience IM, with about one in eight needing to retake a year of studies due to its impact. The emergence of antibiotics for GAS pharyngitis led to a rapid decline in ARF incidence, highlighting the potential impact of targeted infection treatment on autoimmune disease prevention.

Key Findings

• EBV infection is necessary but not sufficient alone to cause MS; molecular mimicry is a favored mechanism.
• EBV establishes latent infection with intermittent reactivation, likely driving MS disease activity.
• GAS infection triggers autoimmune diseases like ARF, serving as a model for EBV-driven MS.
• History of IM doubles the risk of developing MS compared to asymptomatic EBV seroconversion.
• Treating acute IM with antivirals may serve as primary prevention for MS, analogous to antibiotics preventing ARF.
• Current MS therapies may work by targeting memory B cells harboring latent EBV, suggesting antiviral strategies could be effective.

Clinical Implications

Clinicians should recognize infectious mononucleosis as a significant risk factor for MS development and consider the potential benefits of antiviral therapies targeting EBV during acute infection. Development and implementation of rapid diagnostics and effective antiviral treatments for IM could reduce the incidence and progression of MS. Furthermore, prophylactic EBV vaccination may represent a promising strategy to prevent both IM and MS.

Conclusion

The parallels between GAS-driven ARF and EBV-driven MS provide a compelling framework for understanding MS pathogenesis and prevention. Targeting EBV infection through antiviral treatment and vaccination holds promise for reducing MS incidence and improving patient outcomes.

References

1. Epstein–Barr virus and multiple sclerosis link, 2024 -- The Connection Between Post-Streptococcal Autoimmunity and Epstein–Barr Virus as a Possible Contributor to Multiple Sclerosis